Navigation Links
Drug Effective for Diabetic Foot Ulcers

A new study finds the drug dalteparin is beneficial for diabetic patients with severe foot ulcers.// Chronic foot ulcers cause a lot of suffering for diabetic patients and are one of the most expensive diabetic complications. This common complication can threaten the life and limb of the diabetic patient. A new study led by investigators from Karolinska Hospital in Sweden reveals at the effect of the drug dalteparin on foot ulcers in diabetic patients.

For the study, 87 patients were randomly assigned to receive either injections of dalteparin or an injection of a saline solution each day for up to six months. Researchers tracked each patient’s progress to see if the foot ulcer healed or if the patient ended up needing their foot amputated.

Researchers report the patients on dalteparin fared much better than the patients receiving the saline solution. Specifically, 29 patients of the 43 on dalteparin had their ulcers healed or at least saw a 50 percent improvement. In contrast, 20 of the 42 patients in the placebo group saw an improvement. Five patients in both groups had their ulcers get worse. As for amputation, two patients in the dalteparin group had their foot amputated compared to eight in the placebo group.

Study authors write, "The present study shows for the first time that treatment with dalteparin improves the ulcer outcomes in diabetic patients." Researchers add these results need to be confirmed in a larger trial. However, they say the positive effects of this drug on ulcer healing could affect the costs and care of diabetics
'"/>




Page: 1

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: